期刊文献+

石藤胶囊对类风湿性关节炎患者OPG和RANKL的影响 被引量:4

The Effect of Shiteng Capsules on OPG and RANKL of Patients with Rheumatoid Arthritis
下载PDF
导出
摘要 目的:观察石藤胶囊对类风湿性关节炎患者骨保护素(osteoprotegerin,OPG)、核因子κB受体激活配体(re-ceptor activator of NF-κB ligand RANKL)的影响。方法:入选类风湿性关节炎患者随机分为治疗组(30例)和对照组(30例),治疗组用石藤胶囊,对照组用雷公藤多苷,两组同时配以甲氨蝶呤,均服药90天,观察治疗前后两组患者的OPG、RANKL变化。结果:治疗后两组血清RANKL均有明显降低(P<0.05),OPG均有明显提高(P<0.05),两组间比较RANKL和OPG均无统计学意义(P>0.05)。结论:石藤胶囊可以降低类风湿性关节炎患者血清RANKL水平,提高血清OPG水平。 Objective :To observe the effect of Shiteng capsules to osteoprotegerin (OPG) and receptor activator of NK - KB ligand (RANKL) of the patients with RA. Methods :The patients with RA were divided into randomly treatment team(30cases) that was treated with Shiteng capsules and control team(30 cases)that was treated with tripterygium glycosides. Two teams were treated in methotrexate at the same time. All patients were taken 90 days. The changes of the OPG and RANKL were observed in two teams before and after treatment. Results : Blood serum RANKL are low obviously in two teams ( P 〈 0. 05). OPG are high obviously after treatment( P 〈 0. 05 ). There are not statistically significant in RANKL and OPG between two teams (P 〉 0. 05 ). Conclusion : Shiteng capsules can cut down the level of the blood serum RANKL and boost the level of the blood serum OPG of the patients with RA.
出处 《辽宁中医杂志》 CAS 北大核心 2011年第3期422-423,共2页 Liaoning Journal of Traditional Chinese Medicine
关键词 OPG RANKL 类风湿性关节炎 石藤胶囊 OPG RANKL RA shiteng capslues
  • 相关文献

参考文献4

二级参考文献41

  • 1Steven RC,Douglas CB.Do statins prevent cardiovascular disease and fracture? JAMA,2000,283:3255-3258.
  • 2Bengtsson AK,Ryan EJ.Immune function of the decoy recepter osteoprotegerin.Crit Rev Immunol,2002,22:201-205.
  • 3Gravallese EM,Manning C,Tsay A,et al.Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.Arthritis Rheum,2000,43:250-258.
  • 4Zauli G,Rimondi E,Nicolin V,et al.TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.Blood,2004,104:2044-2050
  • 5Hofbauer LC,Khosla S,Dunstan CR,et al.The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res,2000,15:2-12.
  • 6Abdallah BM,Stilgren LS,Nissen N,et al.Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures.Calcif Tissue Int,2005,76:90-97.
  • 7Tsangari H,Findlay DM,Kuliwaba JS,et al.Increased expression of IL-6and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.Bone,2004,35:334-342.
  • 8Coetzee M,Kruger MC.Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio:a new approach to osteoporosis treatment? South Med J,2004,97:506-511.
  • 9Fahrleitner-Pammer A,Dobnig H,Piswanger-Soelkner C,et al.Osteoprotegerin serum levels in women:correlation with age,bone mass,bone turnover and fracture status.Wien Klin Wochenschr,2003,115:291-297.
  • 10Jorgensen HL,Kusk P,Madsen B,et al.Serum osteoprotegerin (OPG)and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios.J Bone Miner Metab,2004,22:132-138.

共引文献20

同被引文献47

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部